For FY2018, the UA has again met or surpassed performance expectations for technology commercialization as TLA continues to bring University inventions from the lab to the world for social and economic benefit. Now, it's time to look forward.

Tucson's newest early-stage capital fund, UA Venture Capital Fund LLC, has announced that it's first investments will be in three UA-connected companies: startups Codelucida, Regulonix and Post.Bid.Ship.

As cancer diagnostics and therapeutics become more personalized, pathologists will require more high-quality tissue from biopsies for testing. To address the challenge, this startup is working to bring a next-generation biopsy instrument invented at the UA to the world.

Over 3 million new cases of skin cancer are diagnosed annually, but we have a natural defense against cancer-causing UV rays: melanin. Now, the UA has licensed two melanin-producing peptides to startup MCR Therapeutics.

In her new position, Rakhi Gibbons now oversees all TLA licensing operations. Learn more about Rakhi and her new role.

Co-founded by UA alumni, the company was recently named to receive a technology development voucher for work on ultra-high purity isotropic graphite. The technology, licensed to Urbix, began as a sponsored project in the College of Optical Sciences.